<DOC>
	<DOCNO>NCT01402024</DOCNO>
	<brief_summary>Chemotherapy induce nausea vomiting ( CINV ) one mostly observe distress toxicity cancer treatment . It occur 90 % case highly emetogenic chemotherapy use . CINV cause disturbance daily living cancer patient reduce compliance treatment Even standard anti-emetic measure 50 % patient suffer complication . Whereas standard anti-emetic guideline exist case adult patient , guideline make pediatric population . The new drug Aprepitant recommend use adult high efficacy , concrete data available child regard use . There retrospective report limit data available regard use Aprepitant child satisfactory efficacy reduce CINV . As randomized large data suggest efficacy routine use child , plan study .</brief_summary>
	<brief_title>Study Evaluate Anti-emetic Effect Aprepitant Versus Placebo Children Adolescent Receiving Chemotherapy</brief_title>
	<detailed_description>Population : Children adolescent ( 5-18 year ) weight 15-65 kg receive highly emetogenic chemotherapy ( HEC ) - - VAC ( vincristine , dactinomycin/Adriamycin , cyclophosphamide ) - ABVD ( adriamycin , bleomycin , vinblastine , dacarbazine ) - Cisplatin/Doxorubicin Sampling technique Subjects meet eligibility criterion randomly assign use random allocation number generate computer one two group . The unit randomization subject first cycle HEC . The patient enrol twice Procedure data collection : 1 . The data collect patient d1 d10 chemotherapy patient receive chemotherapy day care , maximum d3 . 2 . After take consent patient enrol per inclusion exclusion criterion , randomize one two group . All baseline assessment do . Patient explain fill diary . In first 2 day . The subject fill diary investigator supervision , rest fill home . Reinforcement do phone . Procedure double blind - Double blind do intervention . Four different box make capsule . Total 3 capsule 3 day make blister pack , mention d1 , d2 , d3 ( capsule ) . Two different body weight group make : 15-40 kg , 41-65 kg . - Group `` A '' code Aprepitant group group `` B '' code control group . Both patient investigator blind regard medicine code .</detailed_description>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Antiemetics</mesh_term>
	<mesh_term>Emetics</mesh_term>
	<criteria>All subject must confirm diagnosis malignancy receive highly emetogenic chemotherapy first time ( VAC , ABVD CDDP/Doxorubicin ) Age group 518 year weight 1565 kg Children/adolescents caregiver understand Hindi English willing participate study ( write inform consent ) Significant organ dysfunction Active infection Pregnancy Uncontrolled medical condition malignancy Need contraindicate concomitant medication Patients receive chemotherapy VAC , ABVD CDDP/Doxorubicin Treatment another investigational drug within 4 week study start prior Aprepitant use Had receive receive RT abdomen pelvis week prior treatment Vomited 24 hr prior treatment Prior exposure highly emetogenic chemotherapeutics Abnormal lab value ( ANC &lt; 1500/mm3 , TLC &lt; 3000/mm3 , Plt &lt; 100,000/mm3 , AST/ALT &gt; 2.5 time ULN , bill &gt; 1.5 time ULN , S.cr &gt; 1.5 time ULN , patient systemic steroid</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>